[1] Tokmak H, Demir N, Demirkol MO.  Cardiac angiosarcoma: utility of [18F]fluorodeoxyglucose positron emission tomography-computed tomography in evaluation of residue, metastases, and treatment response[J]. Vasc Health Risk Manag, 2014, 10: 399-401.   doi: 10.2147/VHRM.S64286
[2] 邵军, 沈小东.  18F-FDG PET/CT在心脏肿瘤诊断中的临床价值[J]. 全科医学临床与教育, 2017, 15(3): 282-285.   doi: 10.13558/j.cnki.issn1672-3686.2017.03.013
Shao J, Shen XD.  Clinical value of 18F-FDG PET/CT in diagnosis of cardiactumor[J]. Clin Edu Gen Pract, 2017, 15(3): 282-285.   doi: 10.13558/j.cnki.issn1672-3686.2017.03.013
[3] 吴杰婉.  原发性心脏肿瘤的CT及磁共振成像影像学特征[J]. 实用医学影像杂志, 2017, 18(2): 166-167.   doi: 10.16106/j.cnki.cn14-1281/r.2017.02.028
Wu JW.  CT and MRI features of primary cardiac tumors[J]. J Pract Med Imaging, 2017, 18(2): 166-167.   doi: 10.16106/j.cnki.cn14-1281/r.2017.02.028
[4] 卢霞, 孟晶晶, 焦建, 等.  PET/CT诊断右心房血管肉瘤合并心包压塞1例[J]. 中国医学影像技术, 2017, 33(3): 484-.   doi: 10.13929/j.1003-3289.201608077
Lu X, Meng JJ, Jiao J, et al.  PET/CT diagnosis of right atrium hemangioscarcoma with cardiac temponad: case report[J]. Chin J Med Imaging Technol, 2017, 33(3): 484-.   doi: 10.13929/j.1003-3289.201608077
[5] 卢霞, 孟晶晶, 柏江, 等.  18F-FDG PET/CT在心脏肿瘤诊断的临床应用价值[J]. 肿瘤学杂志, 2017, 23(6): 474-478.   doi: 10.11735/j.issn.1671-170X.2017.06.B004
Lu X, Meng JJ, Bai J.  Clinical application value of 18F-FDG PET/CT in diagnosis of cardiac neoplasm[J]. J Oncol, 2017, 23(6): 474-478.   doi: 10.11735/j.issn.1671-170X.2017.06.B004
[6] 王可颜, 程敬亮, 韩星敏, 等.  心脏肿瘤和心外最大肿瘤代谢体积比值在判断心脏肿瘤起源中的应用价值[J]. 中华核医学与分子影像杂志, 2018, 38(3): 178-181.   doi: 10.3760/cma.j.issn.2095-2848.2018.03.007
Wang KY, Cheng JL, Han XM, et al.  Predictive value of the metabolic tumor volume ratio of cardiac mass to maximal extra cardiac mass for the origin of cardiac tumors[J]. Chin J Nucl Med Mol Imaging, 2018, 38(3): 178-181.   doi: 10.3760/cma.j.issn.2095-2848.2018.03.007
[7] 孙龙, 江茂情, 赵龙, 等.  18F-FDG PET/CT在心脏肿瘤诊断中的临床应用[J]. 中华核医学与分子影像杂志, 2013, 33(3): 175-178.   doi: 10.3760/cma.j.issn.2095-2848.2013.03.005
Sun L, Jiang MQ, Zhao L, et al.  Clinical application of 18F-FDG PET/CT for cardiac neoplasm diagnosis[J]. Chin J Nucl Med Mol Imaging, 2013, 33(3): 175-178.   doi: 10.3760/cma.j.issn.2095-2848.2013.03.005
[8] Zhang PL, Li ZY, Wang DQ, et al.  18F-fluorodeoxyglucose positron emission computed tomography for monitoring tumor response in esophageal carcinoma treated with concurrent chemoradiotherapy[J]. Oncol Lett, 2018, 15(2): 1845-1852.   doi: 10.3892/ol.2017.7528
[9] Masuda A, Naya M, Manabe O, et al.  Administration of unfractionated heparin with prolonged fasting could reduce physiological 18F-fluorodeoxyglucose uptake in the heart[J]. Acta Radiol, 2016, 57(6): 661-668.   doi: 10.1177/0284185115600916
[10] Rahbar K, Seifarth H, Schafers M, et al.  Differentiation of malignant and benign cardiac tumors using 18FDG PET/CT[J]. J Nucl Med, 2012, 53(6): 856-863.   doi: 10.2967/jnumed.111.095364
[11] 高平, 王茜.  18F-FDG PET/CT对心脏肿瘤的鉴别诊断价值[J]. 中国医学影像学杂志, 2016, 24(10): 771-774.   doi: 10.3969/j.issn.1005-5185.2016.10.015
Gao P, Wang Q.  Differential diagnosis of 18F-FDG PET/CT in benign and malignant cardiac tumor[J]. Chin J Med Imaging, 2016, 24(10): 771-774.   doi: 10.3969/j.issn.1005-5185.2016.10.015
[12] Kassop D, Donovan MS, Cheezum MK, et al.  Cardiac masses on cardiac CT: a review[J]. Curr Cardiovasc Imaging Rep, 2014, 7(8): 9281-.   doi: 10.1007/s12410-014-9281-1
[13] Cheng G, Alavi A.  The value of 18F-FDG PET/CT in the assessment of cardiac malignancy remains to be defined[J]. J Nucl Med, 2012, 53(10): 1657-1658.   doi: 10.2967/jnumed.112.109611
[14] García Vicente AM, Castrejón ÁS, Relea Calatayud F, et al.  18F-FDG retention index andbiologic prognostic parameters in breast cancer[J]. Clin Nucl Med, 2012, 37(5): 460-466.   doi: 10.1097/RLU.0b013e31823926c9
[15] Shimizu K, Okita R, Saisho S, et al.  Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer[J]. Ann Nucl Med, 2015, 29(10): 854-860.   doi: 10.1007/s12149-015-1013-3
[16] Kuwabara H, Toriihara A, Yuasa-Nakagawa K, et al.  Prognostic value of metabolic tumor burden calculated using dual-time-point 18F-fluorodeoxyglucose positron emission tomography/CT in patients with oropharyngeal or hypopharyngeal cancer[J]. Head Neck, 2019, 41: 103-109.   doi: 10.1002/hed.25490
[17] 王雅雯, 孙晓昕.  18F-FDG显像中抑制心肌生理性摄取的方法研究进展[J]. 中华核医学与分子影像杂志, 2017, 37(5): 305-307.   doi: 10.3760/cma.j.issn.2095-2848.2017.05.013
Wang YW, Sun XX.  Methods of suppressing physiological myocardial uptake in 18F-FDG imaging[J]. Chin J Nucl Med Mol Imaging, 2017, 37(5): 305-307.   doi: 10.3760/cma.j.issn.2095-2848.2017.05.013
[18] Juergens KU, Oei ML, Weckesser M, et al.  Whole-body imaging of oncologic patients using 16-channel PET-CT evaluation of an iv contrast enhanced MDCT protocol[J]. Nuklearmedizin, 2008, 47(1): 30-36.   doi: 10.3413/nukmed-0105
[19] Weckesser M, Stegger L, Juergens KU, et al.  Correlation between respiration-induced thoracic expansion and a shift of central structures[J]. Eur Radiol, 2006, 16(7): 1614-1620.   doi: 10.1007/s00330-005-0097-x
[20] Langah R, Spicer K, Gebregziabher M, et a1.  Effectiveness of prolonged fasting 18F-FDG PET-CT in the detection of cardiac sarcoidosis[J]. J Nuel Cardiol, 2009, 16(5): 801-810.   doi: 10.1007/s12350-009-9110-0
[21] Lee HY, Nam HY, Shin SK.  Comparison of myocardial F-18 FDG uptake between overnight and non-overnight fasting in non-diabetic healthy subjects[J]. Jpn J Radiol, 2015, 33(7): 385-391.   doi: 10.1007/s11604-015-0428-z
[22] Williams G, Kolodny GM.  Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet[J]. AJR Am J Roentgenol, 2008, 190(2): W151-W156.   doi: 10.2214/AJR.07.2409
[23]

Pantiora EV, Kontis EA, Michalaki V, et al. Granuloma mimicking local recurrence on PET/CT after liver resection of colorectal liver metastasis: a case report[J/OL]. Cureus, 2016, 8(8): e717[2019-07-27]. https://assets.cureus.com/uploads/case_report/pdf/4544/1511807065-20171127-18321-j86lw1.pdf. DOI: 10.7759/cureus.717.
[24] De Geeter F, Gykiere P.  18F-FDG PET imaging in granulomatosis with polyangiitis[J]. Hell J Nucl Med, 2016, 19(1): 5-6.   doi: 10.1967/s0024499100331
[25] Bae JM, Lee HY, Choi JY.  False-positive uptake on positron emission tomography/computed tomography immediately after lung biopsy: a case report[J]. Medicine (Baltimore), 2015, 94(44): e1896-.   doi: 10.1097/MD.0000000000001896
[26] Wykrzykowska J, Lehman S, Williams G, et al.  Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation[J]. J Nucl Med, 2009, 50(4): 563-568.   doi: 10.2967/jnumed.108.055616
[27] Rogers IS, Nasir K, Figueroa AL, et al.  Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina[J]. JACC Cardiovasc Imaging, 2010, 3(4): 388-397.   doi: 10.1016/j.jcmg.2010.01.004
[28] Cheng VY, Slomka PJ, Ahlen M, et al.  Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: A randomized controlled trial[J]. J Nucl Cardiol, 2010, 17(2): 286-291.   doi: 10.1007/s12350-009-9179-5
[29] Gaeta C, Fernández Y, Pavía J, et al.  Reduced myocardial 18F-FDG uptake after calcium channel blocker administration. Initial observation for a potential new method to improve plaque detection[J]. Eur J Nucl Med Mol Imaging, 2011, 38(11): 2018-2024.   doi: 10.1007/s00259-011-1873-2
[30] 郁春景, 章斌, 邓胜明, 等.  P-gp影响18F-FDG摄取的体外实验[J]. 中华核医学与分子影像杂志, 2013, 33(3): 213-216.   doi: 10.3760/cma.j.issn.2095-2848.2013.03.014
Yu CJ, Zhang B, Deng SM, et al.  The effect of P-glycoprotein on 18F-FDG uptake in vitro[J]. Chin J Nucl Med Mol Imaging, 2013, 33(3): 213-216.   doi: 10.3760/cma.j.issn.2095-2848.2013.03.014
[31] Nuutila P, Koivisto VA, Knuuti J, et al.  Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo[J]. J Clin Invest, 1992, 89(6): 1767-1774.   doi: 10.1172/JCI115780
[32] Dilsizian V, Bacharach SL, Beanlands RS, et al.  ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography(PET) nuclear cardiology procedures[J]. J Nucl Cardio, 2016, 23(5): 1187-1226.   doi: 10.1007/s12350-016-0522-3
[33] Corrigan AJ, Schleyer PJ, Cook GJ.  Pitfalls and artifacts in the use of PET/CT in oncology imaging[J]. Semin Nucl Med, 2015, 45(6): 481-499.   doi: 10.1053/j.semnuclmed.2015.02.006
[34] Salmon E, Bernard Ir C, Hustinx R.  Pitfalls and limitations of PET/CT in brain imaging[J]. Semin Nucl Med, 2015, 45(6): 541-551.   doi: 10.1053/j.semnuclmed.2015.03.008
[35] Lakhani A, Khan SR, Bharwani N, et al.  FDG PET/CT pitfalls in gynecologic and genitourinary oncologic imaging[J]. Radiographics, 2017, 37(2): 577-594.   doi: 10.1148/rg.2017160059